MARKET

IOVA

IOVA

Iovance Biotherp
NASDAQ
11.00
+0.20
+1.85%
After Hours: 11.02 +0.02 +0.18% 19:57 09/25 EDT
OPEN
10.90
PREV CLOSE
10.80
HIGH
11.13
LOW
10.69
VOLUME
12.63M
TURNOVER
--
52 WEEK HIGH
11.13
52 WEEK LOW
1.760
MARKET CAP
4.98B
P/E (TTM)
-15.2545
1D
5D
1M
3M
1Y
5Y
1D
Iovance Biotherapeutics Price Target Announced at $15.00/Share by Goldman Sachs
Dow Jones · 2d ago
Goldman Sachs Reinstates Buy on Iovance Biotherapeutics, Announces $15 Price Target
Benzinga · 2d ago
Iovance Biotherapeutics resumed with a Buy at Goldman Sachs
TipRanks · 3d ago
Analysts Offer Insights on Healthcare Companies: Palisade Bio (PALI) and Iovance Biotherapeutics (IOVA)
TipRanks · 3d ago
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
NASDAQ · 5d ago
Weekly Report: what happened at IOVA last week (0914-0918)?
Weekly Report · 6d ago
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Barchart · 09/18 16:10
Iovance Biotherapeutics put buyer realizes 64% same-day gains
TipRanks · 09/18 12:00
More
About IOVA
Iovance Biotherapeutics, Inc. is a commercial biotechnology company. The Company is focused on developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Its products include Amtagvi and Proleukin. Amtagvi is indicated for the treatment of adult patients with melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor, with or without a MEK inhibitor. It is marketing Proleukin (aldesleukin), an interleukin-2 (IL-2) product used in the Amtagvi treatment regimen and in other applications. Amtagvi and Proleukin are part of a treatment regimen that includes lymphodepletion. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings and indications for solid tumor cancers. Its TIL therapy includes melanoma, non-small cell lung cancer and gynecologic cancer.

Webull offers Iovance Biotherapeutics Inc stock information, including NASDAQ: IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.